{"doc_id": "si-2025-0418-reg-1", "parent_doc_id": "si-2025-0418", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 418 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) (No.2) Regulations 2025. \n\n(2) The collective citation “the Medicinal Products (Prescription and Control \n\nof Supply) Regulations 2003 to 2025” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no.2) regulation 2025 (2) collective citation medicinal product (prescription control supply) regulation 2003 2025 includes regulation", "start_char": 745, "end_char": 1034, "source_path": "downloads\\2025\\2025_0418.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d2a53e3fd4f4200aa8bff509779d984316167658642e715736bbc16bd5ad607", "cross_refs": []}
{"doc_id": "si-2025-0418-reg-2", "parent_doc_id": "si-2025-0418", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 418 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "In these Regulations –", "text_raw": "2. \n\nIn these Regulations – \n\n“Principal Regulations” means the Medicinal Products (Prescription and Control \nof Supply) Regulations 2003 ( S.I. No. 540 of 2003); \n\n“Regulations of 2024” means the Medicinal Products (Prescription and Control \nof Supply) (Amendment) (No. 5) Regulations 2024 (S.I. No. 582 of 2024). \n\n“Regulations of 2025” means the Medicinal Products (Prescription and Control \nof Supply) (Amendment) Regulations 2025 (S.I. No. 353 of 2025). \n\nNotice of the making of this Statutory Instrument was published in \n\"Iris Oifigiúil\" of 5th September, 2025. \n\n \n \n \n \n \n \n\f[418] 3 \n\nThe Eight Schedule (as amended by Regulation 3 of the Regulations of", "text_norm": "2 regulation - principal regulation mean medicinal product (prescription control supply) regulation 2003 ( s.i no 540 2003) regulation 2024 mean medicinal product (prescription control supply) (amendment) (no 5) regulation 2024 (s.i no 582 2024) regulation 2025 mean medicinal product (prescription control supply) (amendment) regulation 2025 (s.i no 353 2025) notice making statutory instrument published iris oifigiuil 5th september 2025 418 3 eight schedule (as amended regulation 3 regulation", "start_char": 1034, "end_char": 1699, "source_path": "downloads\\2025\\2025_0418.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d2a53e3fd4f4200aa8bff509779d984316167658642e715736bbc16bd5ad607", "cross_refs": []}
{"doc_id": "si-2025-0418-reg-3", "parent_doc_id": "si-2025-0418", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 418 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "2024) to the Principal Regulations is amended by removing the Eight Schedule", "text_raw": "3. \n2024) to the Principal Regulations is amended by removing the Eight Schedule \nin its entirety and inserting the following entry wherever it appears: \n\n“ \n\nMedicinal \nproduct \n\nForm and \npresentation \nof product \nadministered \n\nRoute of \nadministrati\non \n\nIndication \nfor which \nthe \nmedicinal \nproduct may \nbe \nadministered \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministrati\non \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nColumn 6 \n\nEpinephrine \n(adrenaline) \nInjection \n\nIntramuscular \nor \nsubcutaneous \ninjection \n\nEpinephrine \n(adrenaline) \ninjection \npresented as a \npre-filled \nsyringe or \nampoule \n\nGlucagon for \ninjection \n\nGlucagon \nhydrochloride \nfor injection \n\nIntramuscular \nor \nsubcutaneous \ninjection \n\nGlyceryl \ntrinitrate \naerosol \n\nGlyceryl \ntrinitrate \nsublingual \nspray \n\nSublingual \nspray \n\nAdults and \nChildren: For \nthe \nemergency \ntreatment of \nanaphylactic \nshock \n\nAdults and \nchildren: For \nthe \nemergency \ntreatment of \nhypoglycaem\nia \nAdults: For \nthe \nemergency \ntreatment of \nsevere angina \nattack \n\nBy \nintramuscular \ninjection only \n\nPrevention of \nseasonal \ninfluenza \n\nInfluenza \nvaccine \nsuspension \nfor injection \npresented as a \npre-filled \nsyringe \n\nInfluenza \nvaccine of a \ncomposition \nthat has been \napproved for \nuse in the \nEuropean \nUnion for the \nseason in \nquestion \n\nAny place \n\nAny place \n\nAny place \n\nAny suitable \nand \nappropriate \nplace, having \nregard to \npublic \nconvenience \nand the need \nto protect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand relevant \nnational \nguidelines \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered", "text_norm": "3 2024) principal regulation amended removing eight schedule entirety inserting following entry wherever appears medicinal product form presentation product administered route administrati indication medicinal product may administered dosage condition administration place administrati column 1 column 2 column 3 column 4 column 5 column 6 epinephrine (adrenaline) injection intramuscular subcutaneous injection epinephrine (adrenaline) injection presented pre-filled syringe ampoule glucagon injection glucagon hydrochloride injection intramuscular subcutaneous injection glyceryl trinitrate aerosol glyceryl trinitrate sublingual spray sublingual spray adult child emergency treatment anaphylactic shock adult child emergency treatment hypoglycaem ia adult emergency treatment severe angina attack intramuscular injection prevention seasonal influenza influenza vaccine suspension injection presented pre-filled syringe influenza vaccine composition approved use european union season question place place place suitable appropriate place regard public convenience need protect health safety public safely administer product accordance summary product characteristic product administered relevant national guideline accordance summary product characteristic product administered accordance summary product characteristic product administered", "start_char": 1699, "end_char": 3582, "source_path": "downloads\\2025\\2025_0418.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d2a53e3fd4f4200aa8bff509779d984316167658642e715736bbc16bd5ad607", "cross_refs": []}
{"doc_id": "si-2025-0418-reg-0", "parent_doc_id": "si-2025-0418", "section_id": "reg-0", "section_label": "Regulation 0.", "si_number": "S.I. No. 418 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "0.5ml or less", "text_raw": "0.5ml or less \nfor single \nadministration. \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand \nImmunisation \nGuidelines for \nIreland, as \npublished and \nupdated by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by \nthe Minister for \nHealth. Only to \nbe administered \nin connection \nwith the \ncarrying on of \nthe registered \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f4 [418] \n\nInfluenza \nvaccine (live \nattenuated) \nnasal spray \nsuspension \nof a \ncomposition \nthat has been \napproved for \nuse in the \nEuropean \nUnion for \nthe season in \nquestion \n\nInfluenza \nvaccine nasal \nspray, \nsuspension \n\nBy intranasal \nadministratio\nn only \n\nPrevention of \nseasonal \ninfluenza \n\nNaloxone \ninjection \n\nIntramuscular \ninjection \n\nNaloxone \nhydrochloride \ndihydrate \npre-filled \ninjection \n\nNaloxone \nNasal Spray \n\nNasal \nadministratio\nn \n\nNaloxone \nhydrochlori\nde dihydrate \nNasal Spray \nSolution \n\nAdults and \nchildren: \nRespiratory \ndepression \nsecondary to \nknown or \nsuspected \nnarcotic \noverdose \n\nAdults and \nchildren: \nRespiratory \ndepression \nsecondary to \nknown or \nsuspected \nnarcotic \noverdose \n\nretail pharmacy \nbusiness in \nwhich the \nauthorised \nperson is \nemployed or \nengaged. \n\nChildren and \nadolescents \nfrom 2 to 17 \nyears:", "text_norm": "0.5ml le single administration accordance summary product characteristic product administered immunisation guideline ireland published updated national immunisation advisory committee approved minister health administered connection carrying registered 4 418 influenza vaccine (live attenuated) nasal spray suspension composition approved use european union season question influenza vaccine nasal spray suspension intranasal administratio n prevention seasonal influenza naloxone injection intramuscular injection naloxone hydrochloride dihydrate pre-filled injection naloxone nasal spray nasal administratio n naloxone hydrochlori de dihydrate nasal spray solution adult child respiratory depression secondary known suspected narcotic overdose adult child respiratory depression secondary known suspected narcotic overdose retail pharmacy business authorised person employed engaged child adolescent 2 17 year", "start_char": 3582, "end_char": 4880, "source_path": "downloads\\2025\\2025_0418.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d2a53e3fd4f4200aa8bff509779d984316167658642e715736bbc16bd5ad607", "cross_refs": []}
{"doc_id": "si-2025-0418-reg-0", "parent_doc_id": "si-2025-0418", "section_id": "reg-0", "section_label": "Regulation 0.", "si_number": "S.I. No. 418 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "(administered", "text_raw": "0.2 ml \n(administered \nas 0.1 ml per \nnostril). In \naccordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand \nImmunisation \nGuidelines for \nIreland, as \npublished and \nupdated by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by \nthe Minister for \nHealth. Only to \nbe administered \nin connection \nwith the \ncarrying on of \nthe registered \nretail pharmacy \nbusiness in \nwhich the \nauthorised \nperson is \nemployed or \nengaged. \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nor relevant \nnational \nguidelines \nIn \naccordance \nwith the \nsummary of \nproduct \ncharacteristic\ns \nof the \nproduct \n\nAny suitable \nand \nappropriate \nplace, having \nregard to \npublic \nconvenience \nand the need \nto protect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct \n\nAny place \n\nAny place \n\n \n \n\fPneumococcal \nPolysaccharide \nVaccine \nsolution for \ninjection \n\nPneumococca\nl \nPolysaccharid\ne Vaccine \nsolution for \ninjection \n25mcg/0.5ml \nin a pre-filled \nsyringe or \nvial. \n\nBy \nintramuscular \nor \nsubcutaneous \ninjection \n\nActive \nimmunization \nagainst \ndisease \ncaused by the \npneumococca\nl serotypes \nincluded in \nthe vaccine \n\nOral \ninhalation \n\nIntramuscular \n(IM) injection \nonly \n\nAdults and \nchildren: \nFor the \nemergency \ntreatment \nof acute \nasthmatic \nattack \n\nPrevention of \nzoster and \nzoster- \n\nrelated \n\npost- herpetic \nneuralgia \n\nSalbutamol \n100 mcg multidose inhaler \n\nShingrix \npowder \nand suspension \nfor suspension \nfor injection \n\nHerpes zoster \nvaccine \n(recombinant, \nadjuvanted) \n\nSalbutamol \npressurised \ninhalation \nsolution \n100mcg \nmulti-dose \ninhaler \n\nAdjuvanted \nrecombinant \nVaricella \nZoster \nVirus \nglycoprotein \nE \nantigen \n\nPowder and \nsuspension \nfor \nsuspension \nfor \ninjection. \n\nComirnaty \nKP.2 30 \nmicrograms/do\nse dispersion \n\nDispersion \nfor injection \n\nIntramuscular \ninjection \n\nIndicated for \nactive \nimmunisation \nto prevent \n\n[418] 5 \n\nThe premises \nof the retail \npharmacy \nbusiness in \nwhich the \nauthorised \nperson carries \non \nprofessional \npractice \n\nAny place \n\nThe premises \nof the retail \npharmacy \nbusiness in \nwhich the \nauthorised \nperson carries \non \nprofessional \npractice. \n\nAny suitable \nand \nappropriate \nplace, having \n\nadministered or \nrelevant \nnational \nguidelines", "text_norm": "0.2 ml (administered 0.1 ml per nostril) accordance summary product characteristic product administered immunisation guideline ireland published updated national immunisation advisory committee approved minister health administered connection carrying registered retail pharmacy business authorised person employed engaged accordance summary product characteristic product administered relevant national guideline accordance summary product characteristic product suitable appropriate place regard public convenience need protect health safety public safely administer product place place pneumococcal polysaccharide vaccine solution injection pneumococca l polysaccharid e vaccine solution injection 25mcg 0.5ml pre-filled syringe vial intramuscular subcutaneous injection active immunization disease caused pneumococca l serotypes included vaccine oral inhalation intramuscular (im) injection adult child emergency treatment acute asthmatic attack prevention zoster zoster- related post- herpetic neuralgia salbutamol 100 mcg multidose inhaler shingrix powder suspension suspension injection herpes zoster vaccine (recombinant adjuvanted) salbutamol pressurised inhalation solution 100mcg multi-dose inhaler adjuvanted recombinant varicella zoster virus glycoprotein e antigen powder suspension suspension injection comirnaty kp.2 30 microgram se dispersion dispersion injection intramuscular injection indicated active immunisation prevent 418 5 premise retail pharmacy business authorised person carry professional practice place premise retail pharmacy business authorised person carry professional practice suitable appropriate place administered relevant national guideline", "start_char": 4880, "end_char": 7220, "source_path": "downloads\\2025\\2025_0418.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d2a53e3fd4f4200aa8bff509779d984316167658642e715736bbc16bd5ad607", "cross_refs": []}
{"doc_id": "si-2025-0418-reg-0", "parent_doc_id": "si-2025-0418", "section_id": "reg-0", "section_label": "Regulation 0.", "si_number": "S.I. No. 418 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "0.5ml for single", "text_raw": "0.5ml for single \nadministration, \nin accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand the specific \ntiming of, and \nneed for revaccination as \ndetermined by \nthe \nImmunisation \nGuidelines for \nIreland, as \npublished and \nupdated by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by \nthe Minister for \nHealth. \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered or \nrelevant \nnational \nguidelines \nTwo doses of", "text_norm": "0.5ml single administration accordance summary product characteristic product administered specific timing need revaccination determined immunisation guideline ireland published updated national immunisation advisory committee approved minister health accordance summary product characteristic product administered relevant national guideline two dos", "start_char": 7220, "end_char": 7733, "source_path": "downloads\\2025\\2025_0418.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d2a53e3fd4f4200aa8bff509779d984316167658642e715736bbc16bd5ad607", "cross_refs": []}
{"doc_id": "si-2025-0418-reg-0", "parent_doc_id": "si-2025-0418", "section_id": "reg-0", "section_label": "Regulation 0.", "si_number": "S.I. No. 418 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "0.5 mL each in", "text_raw": "0.5 mL each in \naccordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand \nImmunisation \nGuidelines for \nIreland, as \npublished and \nupdated by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by \nthe Minister for \nHealth. \nIn accordance \nwith the \nsummary of \nproduct \n\n \n \n \n \n \n \n \n \n \n\f6 [418] \n\nfor injection \nCOVID-19 \nmRNA \nVaccine \n\nComirnaty \nKP.2 10 \nmicrograms/do\nse dispersion \nfor injection \nCOVID-19 \nmRNA \nVaccine \n\nComirnaty \nKP.2 3 \nmicrograms/do\nse concentrate \nfor dispersion \nCOVID-19 \nmRNA \nVaccine \n\nNuvaxovid \nJN.1 5 \nmicrograms/do\nse dispersion \nfor injection \nCOVID-19 \nVaccine \n(recombinant, \nadjuvanted) \n\nComirnaty \nLP.8.1 \n30 \nmicrograms/do\nse dispersion \nfor injection \nCOVID-19 \n\nCOVID-19 \ncaused by \nSARS-CoV2, in \nindividuals \n12 years of \nage and older \n\nIndicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV2, in children \naged 5 to 11 \nyears. \n\nIndicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV2, in infants \nand children \naged 6 \nmonths to 4 \nyears. \n\nIndicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV-2 \nin individuals \n12 years of \nage and older \n\nIndicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV-\n\ncharacteristics \nand the relevant \nrecommendatio\nns or guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by \nthe Minister for \nHealth. \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nand the relevant \nrecommendatio\nns or guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by \nthe Minister for \nHealth. \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nand the relevant \nrecommendatio\nns or guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by \nthe Minister for \nHealth. \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nand the relevant \nrecommendatio\nns or guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by \nthe Minister for \nHealth. \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nand the relevant \nrecommendatio\n\nregard to \npublic \nconvenience \nand the need \nto protect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nAny suitable \nand \nappropriate \nplace, having \nregard to \npublic \nconvenience \nand the need \nto protect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nAny suitable \nand \nappropriate \nplace, having \nregard to \npublic \nconvenience \nand the need \nto protect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nAny suitable \nand \nappropriate \nplace, having \nregard to \npublic \nconvenience \nand the need \nto protect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nAny suitable \nand \nappropriate \nplace, having \nregard \nto \npublic \n\nDispersion \nfor injection \n\nIntramuscular \ninjection \n\nConcentrate \nfor dispersion \nfor injection \n\nIntramuscular \ninjection \n\nDispersion \nfor injection \n\nIntramuscular \ninjection \n\nDispersion \nfor injection \n\nIntramuscular \ninjection \n\n \n \n \n \n \n \n\fDispersion \nfor injection \n\nIntramuscular \ninjection \n\nConcentrate \nfor dispersion \nfor injection \n\nIntramuscular \ninjection \n\nmRNA \nVaccine \n\nComirnaty \nLP.8.1 \n10 \nmicrograms/do\ndispersion \nse \nfor \ninjection \nCOVID-19 \nmRNA \nVaccine \n\nComirnaty \nLP.8.1 \n3 \nmicrograms/do\nse concentrate \nfor dispersion \nCOVID-19 \nmRNA \nVaccine \n\n”. \n\n[418] 7 \n\n2, in \nindividuals \n12 years of \nage and older \n\nIndicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV2, in children \naged 5 – 11 \nyears. \n\nIndicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV2, in infants \nand children \naged 6 \nmonths to 4 \nyears. \n\nns or guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \napproved by \nthe Minister for \nHealth. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nand the relevant \nrecommendatio\nns or guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \napproved by \nthe Minister for \nHealth. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nand the relevant \nrecommendatio\nns or guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \napproved by \nthe Minister for \nHealth. \n\nconvenience \nand the need \nto protect the \nhealth \nand \nsafety of the \nand \npublic \nsafely \nadminister the \nproduct. \n\nAny suitable \nand \nappropriate \nplace, having \nto \nregard \npublic \nconvenience \nand the need \nto protect the \nhealth \nand \nsafety of the \npublic \nand \nsafely \nadminister the \nproduct. \n\nAny suitable \nand \nappropriate \nplace, having \nregard \nto \npublic \nconvenience \nand the need \nto protect the \nhealth \nand \nsafety of the \nand \npublic \nsafely \nadminister the \nproduct", "text_norm": "0.5 ml accordance summary product characteristic product administered immunisation guideline ireland published updated national immunisation advisory committee approved minister health accordance summary product 6 418 injection covid-19 mrna vaccine comirnaty kp.2 10 microgram se dispersion injection covid-19 mrna vaccine comirnaty kp.2 3 microgram se concentrate dispersion covid-19 mrna vaccine nuvaxovid jn.1 5 microgram se dispersion injection covid-19 vaccine (recombinant adjuvanted) comirnaty lp.8.1 30 microgram se dispersion injection covid-19 covid-19 caused sars-cov2 individual 12 year age older indicated active immunisation prevent covid-19 caused sars-cov2 child aged 5 11 year indicated active immunisation prevent covid-19 caused sars-cov2 infant child aged 6 month 4 year indicated active immunisation prevent covid-19 caused sars-cov-2 individual 12 year age older indicated active immunisation prevent covid-19 caused sars-cov- characteristic relevant recommendatio n guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic relevant recommendatio n guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic relevant recommendatio n guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic relevant recommendatio n guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic relevant recommendatio regard public convenience need protect health safety public safely administer product suitable appropriate place regard public convenience need protect health safety public safely administer product suitable appropriate place regard public convenience need protect health safety public safely administer product suitable appropriate place regard public convenience need protect health safety public safely administer product suitable appropriate place regard public dispersion injection intramuscular injection concentrate dispersion injection intramuscular injection dispersion injection intramuscular injection dispersion injection intramuscular injection dispersion injection intramuscular injection concentrate dispersion injection intramuscular injection mrna vaccine comirnaty lp.8.1 10 microgram dispersion se injection covid-19 mrna vaccine comirnaty lp.8.1 3 microgram se concentrate dispersion covid-19 mrna vaccine  418 7 2 individual 12 year age older indicated active immunisation prevent covid-19 caused sars-cov2 child aged 5 - 11 year indicated active immunisation prevent covid-19 caused sars-cov2 infant child aged 6 month 4 year n guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic relevant recommendatio n guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic relevant recommendatio n guideline issued national immunisation advisory committee approved minister health convenience need protect health safety public safely administer product suitable appropriate place regard public convenience need protect health safety public safely administer product suitable appropriate place regard public convenience need protect health safety public safely administer product", "start_char": 7733, "end_char": 12648, "source_path": "downloads\\2025\\2025_0418.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d2a53e3fd4f4200aa8bff509779d984316167658642e715736bbc16bd5ad607", "cross_refs": []}
{"doc_id": "si-2025-0418-reg-4", "parent_doc_id": "si-2025-0418", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 418 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "4. The Twelfth Schedule (as amended by Regulation 2 of the Regulations", "text_raw": "4. The Twelfth Schedule (as amended by Regulation 2 of the Regulations \nof 2025) to the Principal Regulations is amended by removing the Twelfth \nSchedule in its entirety and inserting the following entry wherever it appears: \n\n“ \n\nMedicinal \nproduct \n\nForm and \npresentation of \nproduct \nadministered \n\nRoute of \nadministration \n\nIndication for \nwhich the \nmedicinal \nproduct may be \nadministered \n\nDosage and \nconditions of \nadministration \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nEpinephrine \n(adrenaline) \ninjection \n\nIntramuscular or \nsubcutaneous \ninjection \n\nEpinephrine \n(adrenaline) \ninjection \npresented as a \npre-filled syringe \nor ampoule \n\nAdults and \nChildren: For the \nemergency \ntreatment of \nanaphylactic \nshock \n\nIn accordance with \nthe summary of \nproduct \ncharacteristics of \nthe product \nadministered and \n\n \n \n \n \n\f8 [418] \n\nInfluenza vaccine \nof a composition \nthat has been \napproved for use \nin the European \nUnion for the \nseason in question \n\nInfluenza vaccine \nsuspension for \ninjection \npresented as a \npre-filled syringe \n\nBy intramuscular \ninjection only \n\nPrevention of \nseasonal \ninfluenza \n\nInfluenza vaccine \nnasal spray, \nsuspension. \n\nBy intranasal \nadministration \nonly. \n\nPrevention of \nseasonal \ninfluenza. \n\nInfluenza vaccine \n(live attenuated) \nnasal spray \nsuspension of a \ncomposition that \nhas been \napproved for use \nin the European \nUnion for the \nseason in question \n\nIntramuscular or \nsubcutaneous \ninjection. \n\nVaccination \nagainst varicella. \n\nVARIVAX \npowder and \nsolvent for \nsuspension for \ninjection in a prefilled syringe. \nVaricella Vaccine \n(live) \n\nPowder and \nsolvent for \nsuspension for \ninjection. White \nto off-white \npowder and \nclear, colourless \nliquid solvent. \n\nIMVANEX \nsuspension for \ninjection \nSmallpox and \nmonkeypox \nvaccine (Live \n\nSuspension for \ninjection. Light \nyellow to pale \nwhite, milky \nsuspension. \n\nSubcutaneous \ninjection. \n\nActive \nimmunisation \nagainst \nsmallpox, \nmonkeypox and \ndisease caused \n\nrelevant national \nguidelines", "text_norm": "4 twelfth schedule (as amended regulation 2 regulation 2025) principal regulation amended removing twelfth schedule entirety inserting following entry wherever appears medicinal product form presentation product administered route administration indication medicinal product may administered dosage condition administration column 1 column 2 column 3 column 4 column 5 epinephrine (adrenaline) injection intramuscular subcutaneous injection epinephrine (adrenaline) injection presented pre-filled syringe ampoule adult child emergency treatment anaphylactic shock accordance summary product characteristic product administered 8 418 influenza vaccine composition approved use european union season question influenza vaccine suspension injection presented pre-filled syringe intramuscular injection prevention seasonal influenza influenza vaccine nasal spray suspension intranasal administration only prevention seasonal influenza influenza vaccine (live attenuated) nasal spray suspension composition approved use european union season question intramuscular subcutaneous injection vaccination varicella varivax powder solvent suspension injection prefilled syringe varicella vaccine (live) powder solvent suspension injection white off-white powder clear colourless liquid solvent imvanex suspension injection smallpox monkeypox vaccine (live suspension injection light yellow pale white milky suspension subcutaneous injection active immunisation smallpox monkeypox disease caused relevant national guideline", "start_char": 12648, "end_char": 14682, "source_path": "downloads\\2025\\2025_0418.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d2a53e3fd4f4200aa8bff509779d984316167658642e715736bbc16bd5ad607", "cross_refs": []}
{"doc_id": "si-2025-0418-reg-0", "parent_doc_id": "si-2025-0418", "section_id": "reg-0", "section_label": "Regulation 0.", "si_number": "S.I. No. 418 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "0.5ml or less for a", "text_raw": "0.5ml or less for a \nsingle \nadministration. In \naccordance with \nthe summary of \nproduct \ncharacteristics of \nthe product \nadministered and \nImmunisation \nGuidelines for \nIreland, as \npublished and \nupdated by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by the \nMinister for \nHealth. \n Children and \nadolescents from 2 \nto 17 years: 0.2 ml \n(administered as", "text_norm": "0.5ml le single administration accordance summary product characteristic product administered immunisation guideline ireland published updated national immunisation advisory committee approved minister health child adolescent 2 17 year 0.2 ml (administered", "start_char": 14682, "end_char": 15060, "source_path": "downloads\\2025\\2025_0418.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d2a53e3fd4f4200aa8bff509779d984316167658642e715736bbc16bd5ad607", "cross_refs": []}
{"doc_id": "si-2025-0418-reg-0", "parent_doc_id": "si-2025-0418", "section_id": "reg-0", "section_label": "Regulation 0.", "si_number": "S.I. No. 418 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "0.1 ml per nostril).", "text_raw": "0.1 ml per nostril). \nIn accordance with \nthe summary of \nproduct \ncharacteristics of \nthe product \nadministered \nand/or relevant \nnational guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by the \nMinister for \nHealth. \nIn accordance with \nthe summary of \nproduct \ncharacteristics of \nthe product \nadministered \nand/or relevant \nnational guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by the \nMinister for \nHealth. \nIn accordance with \nthe summary of \nproduct \ncharacteristics of \nthe product \nadministered \n\n \n \n\fModified \nVaccinia Virus \nAnkara) \n\nBCG VACCINE \nAJV \n\nTuberculin PPD \nRT23 2 T.U./0.1 \nmL \n\nPowder and \nsolvent for \nsuspension for \ninjection. White \ncrystalline \npowder (might be \ndifficult to see \ndue to the small \namount of \npowder in the \nvial). The solvent \nis a colourless \nsolution without \nany visible \nparticles. \n\nSolution for \ninjection \n(injection). Clear, \ncolourless to \npale-yellow \nsolution. \n\nby vaccinia virus \nin adults. \n\nIntradermal \ninjection. \n\nActive \nimmunisation \nagainst \ntuberculosis. \n\nIntradermal \ninjection. \n\nUsed for \nMantoux \ntuberculin skin \ntesting. \n\nIntramuscular or \nsubcutaneous \ninjection. \n\nVaccination \nagainst measles, \nmumps and \nrubella. \n\nM-M-RvaxPro \npowder and \nsolvent for \nsuspension for \ninjection Measles, \nMumps and \nRubella vaccine \n(live) \n\nPowder and \nsolvent for \nsuspension for \ninjection. Before \nreconstitution, \nthe powder is a \nlight yellow \ncompact \ncrystalline cake \nand the solvent is \na clear colourless \nliquid. \n\nPriorix - Powder \nand solvent for \nsolution for \ninjection in a prefilled syringe \nMeasles, Mumps \n\nPowder and \nsolvent for \nsolution for \ninjection in a prefilled syringe. \n\nSubcutaneous or \nintramuscular \ninjection. \n\nActive \nimmunisation \nagainst Measles, \nMumps and \nRubella. \n\n[418] 9 \n\nand/or relevant \nnational guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by the \nMinister for \nHealth. \nIn accordance with \nthe summary of \nproduct \ncharacteristics of \nthe product \nadministered \nand/or relevant \nnational guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by the \nMinister for \nHealth. \n\nIn accordance with \nthe summary of \nproduct \ncharacteristics of \nthe product \nadministered \nand/or relevant \nnational guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by the \nMinister for \nHealth. \nIn accordance with \nthe summary of \nproduct \ncharacteristics of \nthe product \nadministered \nand/or relevant \nnational guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by the \nMinister for \nHealth. \nIn accordance with \nthe summary of \nproduct \ncharacteristics of \nthe product \nadministered \nand/or relevant \n\n \n \n\f10 [418] \n\nand Rubella \nvaccine (live) \n\nComirnaty KP.2 \n30 \nmicrograms/dose \ndispersion for \ninjection COVID19 mRNA \nVaccine \n\nComirnaty KP.2 \n10 \nmicrograms/dose \ndispersion for \ninjection COVID19 mRNA \nVaccine \n\nComirnaty KP.2 \n3 \nmicrograms/dose \nconcentrate for \ndispersion \nCOVID-19 \nmRNA Vaccine \n\nNuvaxovid JN.1 \n5micrograms/dose \ndispersion for \ninjection \nCOVID-19 \nVaccine \n(recombinant, \nadjuvanted) \n\nDispersion for \ninjection \n\nIntramuscular \ninjection \n\nDispersion for \ninjection \n\nIntramuscular \ninjection \n\nConcentrate for \ndispersion for \ninjection \n\nIntramuscular \ninjection \n\nDispersion for \ninjection \n\nIntramuscular \ninjection \n\nnational guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by the \nMinister for \nHealth. \nIn accordance with \nthe summary of \nproduct \ncharacteristics and \nthe relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by the \nMinister for \nHealth. \nIn accordance with \nthe summary of \nproduct \ncharacteristics and \nthe relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by the \nMinister for \nHealth. \nIn accordance with \nthe summary of \nproduct \ncharacteristics and \nthe relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by the \nMinister for \nHealth. \nIn accordance with \nthe summary of \nproduct \ncharacteristics and \nthe relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee as \napproved by the \n\nIndicated for \nactive \nimmunisation to \nprevent COVID19 caused by \nSARS-CoV-2, in \nindividuals 12 \nyears of age and \nolder \n\nIndicated for \nactive \nimmunisation to \nprevent COVID19 caused by \nSARS-CoV-2, in \nchildren aged 5 \nto 11 years. \n\nIndicated for \nactive \nimmunisation to \nprevent COVID19 caused by \nSARS-CoV-2, in \ninfants and \nchildren aged 6 \nmonths to 4 \nyears. \n\nIndicated for \nactive \nimmunisation to \nprevent COVID19 caused by \nSARS-CoV-2 in \nindividuals 12 \nyears of age and \nolder \n\n \n \n \n \n \n\fDispersion for \ninjection \n\nIntramuscular \ninjection \n\nDispersion for \ninjection \n\nIntramuscular \ninjection \n\nConcentrate for \ndispersion for \ninjection \n\nIntramuscular \ninjection \n\nComirnaty LP.8.1 \n30 \nmicrograms/dose \ndispersion for \ninjection COVID19 mRNA \nVaccine \n\nComirnaty LP.8.1 \n10 \nmicrograms/dose \ndispersion \nfor \ninjection COVID19 \nmRNA \nVaccine \n\nComirnaty LP.8.1 \n3 \nmicrograms/dose \nconcentrate \nfor \ndispersion \nCOVID-19 \nmRNA Vaccine \n\nNirsevimab \n\nIntramuscular \n(IM) injection. \n\n50mg in 0.5mL \npre-filled \nsyringe; 100mg \nin 1mL pre-filled \nsyringe. \n\n[418] 11 \n\nMinister for \nHealth. \nIn accordance with \nthe summary of \nproduct \ncharacteristics and \nthe relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \napproved by the \nMinister for \nHealth. \nIn accordance with \nthe summary of \nproduct \ncharacteristics and \nthe relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \napproved by the \nMinister for \nHealth. \nIn accordance with \nthe summary of \nproduct \ncharacteristics and \nthe relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \napproved by the \nMinister for \nHealth. \nIn accordance with \nthe summary of \nproduct \ncharacteristics and \nthe \nrelevant \nrecommendations \nor \nissued \nNational \nImmunisation \nAdvisory \nCommittee and as \nthe \napproved by \nMinister \nfor \nHealth. \n\nguidelines \nthe \nby \n\nIndicated for \nactive \nimmunisation to \nprevent COVID19 caused by \nSARS-CoV-2, in \nindividuals 12 \nyears of age and \nolder \n\nIndicated for \nactive \nimmunisation to \nprevent COVID19 caused by \nSARS-CoV-2, in \nchildren aged 5 – \n11 years. \n\nIndicated for \nactive \nimmunisation to \nprevent COVID19 caused by \nSARS-CoV-2, in \ninfants and \nchildren aged 6 \nmonths to 4 \nyears. \n\nPassive \nimmunisation \nwith nirsevimab \nof all infants who \nare born during \nthe RSV season. \n\nPassive \nimmunisation \nwith nirsevimab \nof all *high-risk \ninfants aged ≤12 \nmonths at \nthe \nstart of their first \nRSV season. \n\nPassive \nimmunisation \n\nInfants \nweight<5kg: \n\nA \n\n \n \n \n\fof \n(0.5ml) \n\ndose \n\nsingle \n50mg \nadministered \nintramuscularly. \n\nInfants weight≥ \n5kg: A single dose \nof 100mg (1.0ml) \nadministered \nintramuscularly. \n\nChildren up to 24 \nmonths entering \ntheir second \nseason: 200 mg \ngiven as 2 x 100 \nmg intramuscular \ninjections. \n\n12 [418] \n\n”. \n\nwith nirsevimab \nof all infants who \n≤6 \nare \naged \nmonths at \nthe \nstart of the RSV \nseason. \n\nPassive \nimmunisation \nwith nirsevimab \nof all ex-preterm \ninfants under 24 \nmonths of age \nwith Chronic \nLung Disease in \ntheir second RSV \nseason. \n\nGIVEN under my Official Seal, \n\n1 September, 2025. \n\nJENNIFER CARROLL MACNEILL, \n\nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f[418] 13", "text_norm": "0.1 ml per nostril) accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic product administered modified vaccinia virus ankara) bcg vaccine ajv tuberculin ppd rt23 2 t.u 0.1 ml powder solvent suspension injection white crystalline powder (might difficult see due small amount powder vial) solvent colourless solution without visible particle solution injection (injection) clear colourless pale-yellow solution vaccinia virus adult intradermal injection active immunisation tuberculosis intradermal injection used mantoux tuberculin skin testing intramuscular subcutaneous injection vaccination measles mumps rubella m-m-rvaxpro powder solvent suspension injection measles mumps rubella vaccine (live) powder solvent suspension injection reconstitution powder light yellow compact crystalline cake solvent clear colourless liquid priorix - powder solvent solution injection prefilled syringe measles mumps powder solvent solution injection prefilled syringe subcutaneous intramuscular injection active immunisation measles mumps rubella 418 9 relevant national guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic product administered relevant 10 418 rubella vaccine (live) comirnaty kp.2 30 microgram dose dispersion injection covid19 mrna vaccine comirnaty kp.2 10 microgram dose dispersion injection covid19 mrna vaccine comirnaty kp.2 3 microgram dose concentrate dispersion covid-19 mrna vaccine nuvaxovid jn.1 5micrograms dose dispersion injection covid-19 vaccine (recombinant adjuvanted) dispersion injection intramuscular injection dispersion injection intramuscular injection concentrate dispersion injection intramuscular injection dispersion injection intramuscular injection national guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee approved indicated active immunisation prevent covid19 caused sars-cov-2 individual 12 year age older indicated active immunisation prevent covid19 caused sars-cov-2 child aged 5 11 year indicated active immunisation prevent covid19 caused sars-cov-2 infant child aged 6 month 4 year indicated active immunisation prevent covid19 caused sars-cov-2 individual 12 year age older dispersion injection intramuscular injection dispersion injection intramuscular injection concentrate dispersion injection intramuscular injection comirnaty lp.8.1 30 microgram dose dispersion injection covid19 mrna vaccine comirnaty lp.8.1 10 microgram dose dispersion injection covid19 mrna vaccine comirnaty lp.8.1 3 microgram dose concentrate dispersion covid-19 mrna vaccine nirsevimab intramuscular (im) injection 50mg 0.5ml pre-filled syringe 100mg 1ml pre-filled syringe 418 11 minister health accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee approved minister health accordance summary product characteristic relevant recommendation issued national immunisation advisory committee approved minister health guideline indicated active immunisation prevent covid19 caused sars-cov-2 individual 12 year age older indicated active immunisation prevent covid19 caused sars-cov-2 child aged 5 - 11 year indicated active immunisation prevent covid19 caused sars-cov-2 infant child aged 6 month 4 year passive immunisation nirsevimab infant born rsv season passive immunisation nirsevimab high-risk infant aged 12 month start first rsv season passive immunisation infant weight 5kg (0.5ml) dose single 50mg administered intramuscularly infant weight 5kg single dose 100mg (1.0ml) administered intramuscularly child 24 month entering second season 200 mg given 2 x 100 mg intramuscular injection 12 418  nirsevimab infant 6 aged month start rsv season passive immunisation nirsevimab ex-preterm infant 24 month age chronic lung disease second rsv season given official seal 1 september 2025 jennifer carroll macneill minister health 418 13", "start_char": 15060, "end_char": 22816, "source_path": "downloads\\2025\\2025_0418.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d2a53e3fd4f4200aa8bff509779d984316167658642e715736bbc16bd5ad607", "cross_refs": []}
{"doc_id": "si-2025-0418-explanatory-note", "parent_doc_id": "si-2025-0418", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 418 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to make amendments and additions to the \nlists of medicinal products in the Eighth and Twelfth Schedules. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No.2) Regulations 2025. \n\n \n \n \n \n \n\f14 [418] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.50 \n\n(DH-605) 30. 9/25. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation make amendment addition list medicinal product eighth twelfth schedule regulation may cited medicinal product (prescription control supply) (amendment) (no.2) regulation 2025 14 418 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.50 (dh-605) 30 9 25 propylon", "start_char": 22816, "end_char": 23819, "source_path": "downloads\\2025\\2025_0418.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d2a53e3fd4f4200aa8bff509779d984316167658642e715736bbc16bd5ad607", "cross_refs": []}
